A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable.

Affiliation auteurs!!!! Error affiliation !!!!
TitreA randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable.
Type de publicationJournal Article
Year of Publication2014
AuteursRouzier R, Morice P, Floquet A, Selle F, Lamhaudie E, Fourchotte V, Pomel C, Fauvet R, Colombo PEmmanuel, Kalbacher E, Follana P, Martin S, Losoin A, Lecuru F, Pautier P, Guyon F, Cottu PH, Joly F, Ghazi Y, Chereau E
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume32
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/jco.2014.32.15_suppl.tps5614